menu
    • menu
    [{"orgOrder":0,"company":"UWELL Biopharma","sponsor":"Tri-Service General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Welgenaleucel","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"UWELL Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UWELL Biopharma \/ Tri-Service General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"UWELL Biopharma \/ Tri-Service General Hospital"},{"orgOrder":0,"company":"UWELL Biopharma","sponsor":"Liaocheng People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Welgenaleucel","moa":"T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"UWELL Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UWELL Biopharma \/ Liaocheng People's Hospital","highestDevelopmentStatusID":"1","companyTruncated":"UWELL Biopharma \/ Liaocheng People's Hospital"},{"orgOrder":0,"company":"UWELL Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NKG2D CAR T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"UWELL Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UWELL Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"UWELL Biopharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by UWELL Biopharma

    Menu

    UWELL Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UWELL Biopharma

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            UWELL Biopharma

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKG2D CAR T-Cell

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma

                            Details : NKG2D CAR T-Cell is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 22, 2021

                            Lead Product(s) : NKG2D CAR T-Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UWELL Biopharma

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            UWELL Biopharma

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Welgenaleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Tri-Service General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

                            Details : Welgenaleucel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 05, 2020

                            Lead Product(s) : Welgenaleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Tri-Service General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            UWELL Biopharma

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            UWELL Biopharma

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Welgenaleucel

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Liaocheng People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

                            Details : Welgenaleucel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 22, 2019

                            Lead Product(s) : Welgenaleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Liaocheng People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth